Compass Therapeutics公司宣布,其随机COMPANION-002研究不仅达到了无进展生存期(PFS)的关键次要终点,更呈现出多项令人鼓舞的额外研究成果。该临床试验结果的突破性进展,为公司在肿瘤免疫治疗领域的创新药物研发注入了强劲动力。
Compass Therapeutics公司宣布,其随机COMPANION-002研究不仅达到了无进展生存期(PFS)的关键次要终点,更呈现出多项令人鼓舞的额外研究成果。该临床试验结果的突破性进展,为公司在肿瘤免疫治疗领域的创新药物研发注入了强劲动力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.